Hormonal
Chronic consumption of high-calorie/obesogenic diets causes maladaptive perturbations in gut-brain signaling, leading to desensitization of vagal afferents and reduced efficacy of appetite-suppressing gut hormones (GLP-1, CCK, PYY), which contributes to the exacerbation of metabolic dysregulation and obesity.
If you have a history of obesity or high-calorie eating, your body's natural 'stop eating' signals (hormones and nerve feedback) may be desensitized. This isn't a failure of willpower; it's a physiological state. To counter this, focus on strategies that naturally stimulate these pathways, such as consuming protein and fiber before carbohydrates (meal sequencing), which has been shown to enhance GLP-1 secretion and improve metabolic control.
Perturbations in the gut–brain axis are increasingly recognized in pathophysiological states linked to obesity. Deficiencies in this communication pathway, such as reduced neural responsiveness to appetite-suppressing gut hormones, are believed to contribute to the exacerbation of metabolic dysregulation in obesity [38,63].
Why this rating
The paper is a high-impact review citing multiple human and mouse studies, though it synthesizes existing data rather than presenting new primary clinical trial results.
Source
Neuroendocrine gut–brain signaling in obesity
Tim Gruber et al. · Trends in Endocrinology and Metabolism · 2024
DOI 10.1016/j.tem.2024.05.002
More from this paper
- Consuming protein and/or fiber before carbohydrates (meal sequencing) enhances GLP-1 secretion, delays gastric emptying, and improves postprandial glucose and lipid metabolism compared to consuming carbohydrates first.Good
- High-fat diets, specifically saturated lipids like palmitic acid, disturb gastrointestinal feedback and promote overconsumption independently of food palatability.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →